Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM K PLUNKETT JR and XIAOJUN LIU.
Connection Strength
2.044
-
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug; 31(8):373-80.
Score: 0.427
-
Sapacitabine for cancer. Expert Opin Investig Drugs. 2012 Apr; 21(4):541-55.
Score: 0.416
-
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010 Sep 09; 116(10):1737-46.
Score: 0.369
-
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther. 2008 Jan; 7(1):133-42.
Score: 0.313
-
Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 2005 Aug 01; 65(15):6874-81.
Score: 0.265
-
DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIa inhibitor. Mol Pharmacol. 2011 Aug; 80(2):321-7.
Score: 0.099
-
Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res. 2008 May 15; 68(10):3881-9.
Score: 0.080
-
Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Mol Cancer Ther. 2007 May; 6(5):1501-8.
Score: 0.075